| 查看: 578 | 回复: 1 | ||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | ||
[求助]
请帮忙翻译一段摘要，非常感谢
|
||
|
PURPOSE: Our goal was to compare the analgesic efficacy and safety of single doses of intravenous parecoxib sodium, a prodrug of the novel cyclooxygenase (COX)-2-selective inhibitor valdecoxib, with intravenous ketorolac and placebo in postoperative oral surgery patients. PATIENTS AND METHODS: Eligible patients experiencing moderate to severe pain within 6 hours of surgery to extract 2 or more impacted third molars were randomized to receive a single dose of parecoxib sodium 1, 2, 5, 10, 20, 50, or 100 mg; ketorolac 30 mg; or placebo. Analgesic efficacy was assessed over a 24-hour treatment period or until rescue analgesia was required. RESULTS: Parecoxib sodium doses (particularly 50 and 100 mg) had a rapid onset of analgesia (within 11 minutes). The analgesic efficacy of parecoxib sodium 20 to 100 mg was similar to that of ketorolac 30 mg. Parecoxib sodium doses below 20 mg had suboptimal analgesic activity compared with placebo and ketorolac. A plateau of efficacy was observed at the parecoxib sodium 50-mg dose. Parecoxib sodium 50 and 100 mg had a significantly longer duration of analgesia than ketorolac 30 mg. All doses of parecoxib sodium were well tolerated. CONCLUSIONS: Parecoxib sodium, a novel parenteral prodrug of the COX-2-selective inhibitor valdecoxib, is as effective and longer acting at 50- and 100-mg intravenous doses than a standard dose of ketorolac 30 mg intravenously. Parecoxib sodium appears to be safe and well tolerated and, therefore, merits further evaluation in other models of postsurgical pain. |
回复此楼» 猜你喜欢
河北省自然科学基金
已经有8人回复
-
西安交大新媒学院副院长用撤稿论文结题
已经有5人回复
-
论文撤稿了
已经有5人回复
-
某211大学教师把个人教师官方主页改成:我跑了我跑了我跑了!官宣跑路！
已经有5人回复
-
26/27申博自荐
已经有9人回复
-
售SCI一区T0P文章，我:8.O.5.5.1.O.5.4,科目齐全,可+急
已经有3人回复
-
售SCI一区T0P文章，我:8.O.5.5.1.O.5.4,科目齐全,可+急
已经有7人回复
-
揭秘青基评审内幕：几个A才能顺利中标
已经有4人回复
-
青B发送上会通知了吗
已经有7人回复
-
博士申请
已经有3人回复
zjpa
木虫 (正式写手)
- 翻译EPI: 17
- 应助: 13 (小学生)
- 金币: 1897.4
- 散金: 88
- 红花: 8
- 帖子: 446
- 在线: 156.2小时
- 虫号: 1258721
- 注册: 2011-04-08
- 性别: MM
- 专业: 药物分析
【答案】应助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
霜叶: 金币+40, 翻译EPI+1, ★★★★★最佳答案, 非常感谢！ 2013-01-18 14:53:08
霜叶: 金币+40, 翻译EPI+1, ★★★★★最佳答案, 非常感谢！ 2013-01-18 14:53:08
|
目的： 我们的目标是比较单剂量静脉给药帕瑞昔布钠--新型环氧合酶（COX）-2选择性抑制剂伐地考昔的前体药物，与静脉给药酮咯酸和安慰剂对口腔手术患者术后镇痛的有效性和安全性。 患者和方法： 符合条件的患者---拔除2颗或更多颗智齿手术后6小时内有中度至重度疼痛的患者，被随机分配接受单剂量帕瑞昔布钠1、2、5、10、20、50或100毫克，酮咯酸30毫克或安慰剂。在给药后超过24小时期间或直到需要止痛前，对镇痛效果进行评价。 帕瑞昔布钠剂量（特别是50和100毫克）具有速效镇痛作用（11分钟内）。帕瑞昔布钠20-100毫克的镇痛效果与酮咯酸30毫克的镇痛效果类似。低于20毫克的帕瑞昔布钠剂量的镇痛活性，不及安慰剂和酮咯酸。帕瑞昔布钠50毫克剂量观察到疗效达到稳定水平。帕瑞昔布钠50和100毫克有与酮咯酸30毫克相比，镇痛作用持续时间更长。帕瑞昔布钠的所有剂量均具有良好的耐受性。 结论： 帕瑞昔布钠，一种新型COX-2选择性抑制剂伐地考昔的静脉用前体药物，以50 - 100毫克剂量静脉给药，与标准剂量酮咯酸30毫克静脉给药相比，具有良好且持续时间较长的镇痛作用。帕瑞昔布钠安全且耐受性良好，因此，值得在术后疼痛模型中进一步研究。 |
2楼2013-01-18 11:07:26
10